Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: publication key en

PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery

J. Foloppe et al. SITC 2026 – Abstract available on the SITC website – Download the Abstract– Download the Poster

Published 3 November 2026
Categorized as -others, 2026, 2026, Publication, publication key en

Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties

A. Agaoua et al. frontiers in Bioengineering and Biotechnology – Article available on the frontiers website – Download the Article

Published 15 October 2026
Categorized as -others, 2026, 2026, Publication, publication key en

A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial

C. Ottensmeier, et al. Article available on Nature Communications website – Download the Article

Published 2 September 2026
Categorized as 2026, Myvac, Publication, publication key en, TG4050

Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms

A. Agaoua et al. International Oncolytic Virus Conference 2026 – Download the Abstract – Download the Poster

Published 26 April 2026
Categorized as -others, 2026, 2026, Publication, publication key en

TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment

K. Bidet-Huang World Vaccine Congress 2026 – Download the Oral Presentation

Published 1 April 2026
Categorized as 2026, Myvac, Publication, publication key en, TG4050

Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial

C. Ottensmeier, et al. medRxiv Preprint available on medRxiv website – Download the Article

Published 9 January 2026
Categorized as 2026, Myvac, Publication, publication key en, TG4050

VacDesignR®: a Tool for Optimizing Recombinant Poxvirus Vaccine Production

B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster

Published 12 November 2025
Categorized as 2025, Myvac, Publication, publication key en, TG4050

Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC

C. Le Tourneau, et al. SITC 2025 Abstract available on JITC website – Download the abstract – Download the Poster

Published 7 November 2025
Categorized as 2025, Myvac, Publication, publication key en, TG4050

Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors

C. Lebbe, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster

Published 20 October 2025
Categorized as 2025, BT-001, Publication, publication key en

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)

C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Rapid Oral Presentation

Published 22 May 2025
Categorized as 2025, Myvac, Publication, publication key en, TG4050

Posts pagination

Page 1 Page 2 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu